Bionano net loss widens 8.26% to $7.42 million in Q2 FY26; revenue rises 21% to $8.2 million
BNGO•Bionano reports higher Q2 revenue and wider net loss
Bionano Genomics reported Q2 revenue of $8.2 million, up 21% year over year, as consumables rose 31% to $4.3 million.
Net loss widened to $7.42 million, while gross margin edged up 1 percentage point to 53%.
Flow-cell volume climbed 27% to 9,219, while operating expenses increased 2% to $11.5 million.
Management cites adoption of optical genome mapping and gives guidance
Management cited accelerating global adoption of optical genome mapping, driven mainly by increased clinical adoption and higher utilization at clinical sites.
The company issued Q3 revenue guidance of $8.2 million-$8.6 million and maintained full-year guidance of $31 million-$33 million.
